Today, ASTRO brought together leaders from industry and across the field for our inaugural AI Roundtable to discuss the evolving role of artificial intelligence in radiation oncology and patient care. Thank you to Fuse Oncology, MedLever, Novartis, Siemens Healthineers and Merck for sponsoring this important conversation. Learn more about ASTRO's AI initiatives Rad Onc Report on AI: ow.ly/3oH150Z4RQW Spring 2026 ASTROnews article: ow.ly/wsQX50Z4RQU #RadOnc #AI @fuseoncology @MedLever @Novartis @SiemensHealth @Merck @NehaVapiwala

@ASTRO_org is grateful to all who have shared their situation & continues to seek member feedback @ our dedicated Payer Support and Resolution Center resource page. 🙏🏽 astro.org/advocacy/payer-res…

Cancer’s impact transcends borders. Mission-driven @ASTRO_org members like @TamerRefaatMD are leading ASTRO’s charge to address #radiotherapy care access & quality on a global scale. His words are inspiring, but it’s his actions - alongside those of many other committed colleagues - that will move the needle. Come listen & learn how to get more involved!

**ANNOUNCEMENT** Our growth continues with strategic expansions and our recruiting for FOUR (yes 4) new physicians to join our remarkable team! Includes the Vice Chair of Research, Director of Brachytherapy, and two additional clinical-academic faculty positions Read more... @NicholasZaorsky @angela_jia_ @lauren_henke @Soum_Roy_RadOnc @HaleyPerlow @APrice_BeamOn @NRGonc @ACRORadOnc @ARRO_org @ASCO @IJROBP @RadOncUH @a_dalpra @AmarUKishan @HimanshuNagarMD @PCFnews @urotoday

ASTRO is deeply disturbed by the inaccurate, inappropriate, and irresponsible NBC News piece on IORT. We feel this story harms care for breast cancer patients & have strongly rebutted it through our Breast Cancer Resource Panel & a letter from ASTRO CEO, Vivek S Kavadi, MD to NBC News. Read each here: Breast Resource Panel Statement ow.ly/aicz50X9ty1 Letter to NBC News from Dr. Vivek S. Kavadi ow.ly/Hvy550X9txZ

Missing #ASTRO25 already? Watch ASTRO's 2025 Annual Meeting onDemand. Access more than 200 hours of scientific and educational content from leading experts & claim 190 AMA PRA Category 1™ CME credits. All available on the 2025 Annual Meeting Portal. Learn more and purchase now: ow.ly/mRJ650X5L5p

Terrific thread by @seanmmcbride While it is important to keep an open mind when faced with bizarre results, the raw survival numbers are almost incomprehensible. In the ITT population: - In the IMRT arm, there were 29 recurrences (Table 1) and 23 deaths due to cancer (Table S1). - In the IMPT arm, there were 25 recurrences and 11 deaths due to cancer. - Thus, 79% of IMRT recurrences led to cancer-specific mortality, versus only 44% of IMPT recurrences. In the PP population: - In the IMRT arm, there were 23 recurrences and 27 deaths (Fig 3b), of which 10 were without progression (Table 1). We don’t know further causes of death. - In the IMPT arm, there were 23 recurrences and only 16 deaths, of which 9 were without progression. - Thus, 74% (17/23) IMRT recurrent patients died, and only 30% (7/23) IMPT recurrent patients died. These survival after salvage numbers aren’t just statistically significant, they are miraculous. To have 70% of R/M HNSCC alive after IMPT has to reflect something beyond biology. I’m looking forward to the final publication and analysis, but there is a “know it when you see it" phenomenon with confounding, and that appears to hold here.

🚀 Instant Documentation, Zero Hassle In just 2-5 minutes, you can complete clinical radiotherapy documentation and launch all care paths from a single interaction. ✅ Fast: Generate high-quality, customized documents instantly ✅ Smart: Automation ensures accuracy and consistency ✅ Seamless: Signed documents sync directly with your EMR ⚡ Work smarter, streamline documentation, and stay focused on patient care. 📍 lnkd.in/gxtf2vWw

🤝 True Partnership, Real Impact with MedLever At MedLever, we understand the importance of true partnership. When we collaborate with clinics, it's about creating workflows that work best for them. From the initial implementation to ongoing revisions, we're committed to optimizing the platform to fit each clinic's unique needs. Our focus is on: ✨ Customization – Tailoring workflows to your specific processes ✨ Personalization – Adapting the platform to meet your goals ✨ Collaboration – Partnering with your team for continuous improvement With MedLever, clinics gain a lifetime commitment to support and assistance—because patient outcomes come first.

As we look back and reflect on a year of growth, innovation, and collaboration. 2024's achievements have brought us closer to our mission of advancing patient care and operational excellence. Thank you to our clients and partners for making this success possible—here’s to an even brighter 2025! 🌱

9/ Revolutionizing workflows with our end to end custom built learning health system for radonc with @MedLever. Led by @RaedZuhour , our team built a learning radiation oncology EMR—fully automating orders, documentation, nursing tasks, billing, and physics workflows. Gets better and better every iteration.

We are one week away from the #ASTRO23 Annual Meeting & there is still time to register! Register today: ow.ly/Ov2Y50POm10

Are you attending #ASTRO23? Come check us out at Booth 3523. @medlever is the air-traffic control for your clinic and the digital assistant for your #radonc workflow. See our automation engine simplify documentation and our electronic task-tracking whiteboards keep the whole department in sync. See you in San Diego!

Help your #radonc team spend less time on paperwork and more time on patient care. Register: us02web.zoom.us/webinar/regi… #radonc #HealthcareInnovation #rpa #Automation

Register here: us02web.zoom.us/webinar/regi…

**HIRING @ UH Seidman Cancer Center's @RadOncUH** Calling Medical Physicists- We are recruiting! Excited to announce we have grown by >40% in past 2 yrs, and have 4 new LINACs soon to go live and innovative new software @MedLever @RaySearch @KashaniRojano @DrSpratticus

A new year brings new breakthroughs in #oncology. In 2023, the oncology space will focus on: 🟣 Genetic Testing 🟣 Targeted Immunotherapies 🟣 Finding and Treating Cancer at the Same Time 🟣 And More! What are you most excited to see in the oncology space in the new year?

From fee-for-service to value-based care, it's clear that internal processes for clinics are evolving. With value-based care built on the basis of quality of care provided, providers are being rewarded for efficiency & effectiveness. How is your clinic tracking these services?

Happy Holidays from the Medlever team! We wish you all a happy & safe holiday season! 🎄 #happyholidays

Results are important, wouldn't you agree? Medlever is standardizing #oncology data through electronic forms & questionnaires. Numbers on paper are just numbers on paper. Allow your data to become useful for you & your patients.